CROSSJECT chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.21
Dividend & YieldN/A€ (N/A)
Beta 1.3
Market capitalization 168.39M
Operating cash flow -6.82M
ESG Scores unknown

Company description

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its under development drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Epinephrine for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of opioid overdose; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 2001 and is based in Dijon, France.

Sector: Healthcare - Industry: Medical Instruments & Supplies

Financial Ratios
Quick Ratio2.12
Working Capital-1.28
Return On Equity1.99
Debt To Equity-4.34
Fixed Asset Ratio0
Fixed Interest Cover-15.28

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities
Total Cashflows From Investing Activities -3.27M -4.4M -6.1M -6.73M
Net Borrowings 9.3M 9.84M 11.93M 12.28M
Total Cash From Financing Activities 13.3M 13M 11.93M 14.52M
Change To Operating Activities -1.02M -1.7M -482.12k -327.32k
Issuance Of Stock 4M 3.15M
Net Income -10.71M -7.17M -9.84M -10.81M
Change In Cash 2.01M 3.09M 371.38k 1.71M
Effect Of Exchange Rate
Total Cash From Operating Activities -8.02M -5.51M -5.46M -6.08M
Depreciation 2.97M 3.63M 3.95M 811k
Change To Account Receivables
Other Cashflows From Financing Activities 2.24M 2.24M 2.24M 2.24M
Change To Netincome 749.68k -272.28k 913.91k 559.61k
Capital Expenditures -3.27M -4.4M -6.1M -6.73M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -12.3M -8.51M -11.49M -12.62M
Net Income -10.71M -7.17M -9.84M -10.81M
Selling General Administrative 3.97M 4.31M 5.33M 6.18M
Gross Profit -4.57M -1.47M -343k -205k
Ebit -11.56M -8.64M -10.67M -11.82M
Operating Income -11.56M -8.64M -10.67M -11.82M
Interest Expense -222.64k -27k -307k -330k
Income Tax Expense -1.59M -1.34M -1.65M -1.82M
Total Revenue 2.44M 4.9M 4.84M 6.48M
Cost Of Revenue 7.01M 6.37M 5.19M 6.68M
Total Other Income ExpenseNet -747.25k 133.2k -818k -801k
Net Income From Continuing Ops -10.71M -7.17M -9.84M -10.81M
Net Income Applicable To Common Shares -10.71M -7.17M -9.84M -10.81M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 18.5M 21.48M 34.72M 37.01M
Total Stockholder Equity 1.65M 3.01M -1.13M -5.48M
Other Current Liabilities 63.57k 2.56M 3.3M 2.38M
Total Assets 20.16M 24.49M 33.59M 31.52M
Common Stock 13.6M 2.02M 2.39M 2.6M
Other Current Assets 159.35k 62.1k 267k 294k
Retained Earnings -13.84M -7.17M -10.73M -14.79M
Treasury Stock 1 6.29M 665k
Cash 4.76M 7.8M 8.13M 9.83M
Total Current Liabilities 3.22M 2.73M 7.05M 6.67M
Other Stockholder Equity 1 6.29M 665k
Property, Plant, and Equipment 6.34M 5.78M 6.75M 7.15M
Total Current Assets 8.55M 11.77M 18.31M 13.49M
Net Tangible Assets 1.62M 2.98M -1.14M -5.5M
Net Receivables 1.83M 2.03M 8.09M 1.67M
Accounts Payable 2.57M 1.91M 2.35M 1.96M


Insider Transactions

Here are the insider transactions of stock shares related to CROSSJECT:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to CROSSJECT. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on CROSSJECT

Here is the result of two systematic investment strategies applied to CROSSJECT. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on CROSSJECT

The following chart shows the equity curve of the two systematic investment strategies applied to CROSSJECT:

CROSSJECT automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 14.16% on the backtest period.

Performance at glance

Performance

14.16 %

Latent gain

248.45 €

Invested capital

1754.49 €

Annualized return

3.47 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on CROSSJECT

This is the result of two momentum investment strategies applied to CROSSJECT. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on CROSSJECT

The following chart shows all the entries opened by the momentum investment system on CROSSJECT:

CROSSJECT momentum entries
  • The first momentum investment strategy would give 60.13% of return on CROSSJECT. That represents 2707.75€ of latent gain with 4503.48€ of employed capital.
  • The second momentum investment strategy would give 57.19% of return on CROSSJECT. That represents 1573.07€ of latent gain with 2750.55€ of employed capital.
Performance at glance (1Q Momentum)

Performance

60.13 %

Latent gain

2707.75 €

Invested capital

4503.48 €

Annualized return

51.06 %
Performance at glance (2Q Momentum)

Performance

57.19 %

Latent gain

1573.07 €

Invested capital

2750.55 €

Annualized return

15.89 %

Momentum equity curve on CROSSJECT

The following chart shows the equity curve of the two momentum strategies applied to CROSSJECT:

CROSSJECT momentum equity

Note: the dividends potentially given by CROSSJECT are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CROSSJECT

The following chart shows the employed capital evolution of the two momentum strategies on CROSSJECT since the beginning:

CROSSJECT

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250€, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000€.


Buy the dip strategy result on CROSSJECT

Buy the dip entry openings on CROSSJECT

CROSSJECT

The performance achieved by the robo-advisor on CROSSJECT is 106.21%. That represents 1060.51$ of latent gain with 998.51€ of employed capital. The following chart shows CROSSJECT stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of CROSSJECT, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

106.21 %

Latent gain

1060.51 €

Invested capital

998.51 €

Annualized return

51.06 %

Equity curve of the strategy applied to CROSSJECT

The following chart shows the result of the investment strategy applied to CROSSJECT:

CROSSJECT

Note: the dividends potentially given by CROSSJECT are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on CROSSJECT

The following chart shows the employed capital evolution since the beginning of the investment strategy on CROSSJECT:

CROSSJECT

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on CROSSJECT

In this section, I will compare the three previous investment strategies applied to CROSSJECT.

Equity curve comparison on CROSSJECT

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

CROSSJECT investment strategy comparison

Employed capital comparison on CROSSJECT

CROSSJECT investment comparison

Performance comparison on CROSSJECT

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 14.16% 248.45€ 1754.49€ 3.47%
Momentum 1 quarter 60.13% 2707.75€ 4503.48€ 15.66%
Momentum 2 quarters 57.19% 1573.07€ 2750.55€ 15.89%
Non-directional 106.21% 1060.51€ 998.51€ 51.06%
Annualized return comparison

Automatic investment

3.47 %

Momentum 1Q

15.89 %

Momentum 2Q

15.89 %

Non-directional

51.06 %

Correlated stocks

Here are the most positively and negatively correlated stocks with CROSSJECT:

Positive correlations

Most correlated stocks this year

  • CROSSJECT

  • Most correlated stocks last 3 months

  • CROSSJECT

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • CIRCLE PROPERTY PLC ORD NPV
  • CHASEN^

  • Note: The algorithm computes the probability of correlation between CROSSJECT and the other stocks. There may be false positives or some missing correlated stocks. If the price of CROSSJECT does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name CROSSJECT
    Country France
    City Dijon
    Address 6 Rue Pauline Kergomard
    Phone 33 3 80 54 98 50
    Website www.crossject.com
    FullTime employees 96
    Industry Medical Instruments & Supplies
    Sector Healthcare
    Exchange XPAR
    Ticker ALCJ.XPAR
    Market www.euronext.com

    CROSSJECT ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown